tetano
Editor, Senior Moderator
Drugs. 2018 Apr 5. doi: 10.1007/s40265-018-0899-1. [Epub ahead of print]
[h=1]Baloxavir: First Global Approval.[/h] Heo YA[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Baloxavir marboxil (Xofluza?; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.
PMID: 29623652 DOI: 10.1007/s40265-018-0899-1
[h=1]Baloxavir: First Global Approval.[/h] Heo YA[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Baloxavir marboxil (Xofluza?; baloxavir) is an oral cap-dependent endonuclease inhibitor that has been developed by Roche and Shionogi. The drug blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. In February 2018, baloxavir received its first global approval in Japan for the treatment of influenza A or B virus infections. Phase III development is underway in the USA, EU and other countries for this indication. This article summarized the milestones in the development of baloxavir leading to this first global approval for influenza A or B virus infections.
PMID: 29623652 DOI: 10.1007/s40265-018-0899-1